A Study to Evaluate Subcutaneous Durvalumab in Patients with Non-Small Cell Lung Cancer and Small Cell Lung Cancer

Trial Identifier: D9072C00001
Sponsor: AstraZeneca
NCTID:: NCT04870112
Start Date: June 2021
Primary Completion Date: August 2023
Study Completion Date: August 2023
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
BR Porto Alegre, BR, 90035-903
CZ Olomouc, CZ, 775 21
CZ Ostrava - Vitkovice, CZ, 703 84
CZ Praha, CZ, 180 81
CZ Praha, CZ, 140 59
CZ Praha 5, CZ, CZ-150 18
ES Badalona, ES, 08916
ES Madrid, ES, 28041
ES Majadahonda, ES, 28222
ES Sevilla, ES, 41009
NZ Christchurch, NZ, 8011
SG Singapore, SG, 119228
SG Singapore, SG, 169610
SG Singapore, SG, 308433
TR Ankara, TR, 06340
TR Ankara, TR, 06520
TR Istanbul, TR, 31755
TR Izmir, TR, 35340
TR Kayseri, TR, 38039
TW Taichung, TW, 40705
TW Taipei, TW, 235
TW Taipei City, TW, 11217
TW Taipei City, TW, 114
US, AZ Tucson, AZ, US, 85704
US, AZ Tucson, AZ, US, 85711
US, GA Augusta, GA, US, 30912
US, KY Lexington, KY, US, 40536
US, MT Billings, MT, US, 59101
US, TX Houston, TX, US, 77090
US, VA Fairfax, VA, US, 22031